Written by DelveInsight• Jul 10, 2018• 3:30 pm• Articles, Business Consultant, Pharma Consultant

Allergic Conjunctivitis (AC)- Market Insights, Epidemiology and Market Forecast- 2027

allergic conjunctivitis

(Visited 18 times, 1 visits today)

← Previous Story
Allergic Conjunctivitis (AC) – Common disorder with increasing prevalence

→

transthyretin amyloidosis

Next Story
Notizia

Related Posts

Pharma News

Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition

Dec 12, 2019• Business Consultant, DelveInsight's Oncology based Reports, Notizia, Pharma Consultant, The Business Cocktail

A leading global international investment firm, Omega Funds has announced the closure of its sixth fundraising USD 438 Million. More than...

pharma news

Acquisition of ArQule; Synthorx; and Zentalis nabs a raise

Dec 10, 2019• Business Consultant, DelveInsight's Drug Report, Notizia, Oncology based Indications, Pharma Consultant, The Business Cocktail

Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay...

Pharma News

EicOsis receives USD 15M to fuel its non-opioid pain therapy; Alexion Pharmaceuticals buys Achillion Pharmaceuticals; Ipsen adds another drug to its rare disease pipeline

Oct 17, 2019• Business Consultant, DelveInsight's Drug Report, Pharma Consultant, The Business Cocktail

EicOsis has received USD 15Million grant from the National Institute of Drug Abuse (NIDA) to fund the clinical trials of non-opioid pain...

Allergic Conjunctivitis Market

Allergic Conjunctivitis Therapy Market and pipeline analysis

Sep 2, 2019• Articles, Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, Pharma Consultant

More than 50 million Americans suffer from allergies each year. They are the 6th leading cause of chronic illness in the U.S. with an...

Leave a Reply Cancel reply